Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

NCT05652478 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

NIH

Sponsor class

Conditions

Healthy Volunteer
Weight Gain
Metabolic Effects
Integrase Strand Transfer Inhibitors

Interventions

DRUG: Dolutegravir (DTG) AND Tenofovir alafenamide (TAF)
DRUG: Tenofovir Disoproxil Fumarate
DRUG: Dolutegravir
DRUG: Tenofovir alafenamide

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)